Sarah Holstein
Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sarah Holstein as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:29 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT07887984 · Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaAlliance for Clinical Trials in Oncology · not yet recruiting · Multiple Myeloma (MM) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:29 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 625 citationsRCR 29.5
- 160 citationsRCR 15.0
- 151 citationsRCR 4.7
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Br J Haematol · 201737 citationsRCR 1.2
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Blood Cancer J · 202435 citationsRCR 4.3
- Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.Blood Cancer J · 202435 citationsRCR 4.2
- Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.Br J Haematol · 202224 citationsRCR 1.8
- Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.Blood · 20258 citationsRCR 1.4
- Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.Biol Blood Marrow Transplant · 20206 citationsRCR 0.3
- 5 citationsRCR 0.6